首页 > 市场调查报告书 > 製药

精神疾病

市场调查报告书

商品编码

1478072

全球发作性睡病药物市场规模、份额、成长分析、按发作性睡病类型、治疗方法、最终用户 - 产业预测 2024-2031

Global Narcolepsy Drugs Market Size, Share, Growth Analysis, By Narcolepsy Type, By Therapeutics, By End User - Industry Forecast 2024-2031

出版日期: 2024年05月06日 | 出版商:

SkyQuest | 英文 219 Pages | 商品交期: 3-5个工作天内

价格

简介目录

全球发作性睡病药物市场预计将从2022 年的32.1 亿美元成长，从2023 年的35.2 亿美元成长到2031 年达到73.2 亿美元，在预测期内（2024-2031 年）复合年增长率为9.60 %。

发作性睡病药物市场主要是由人口老化所推动的，他们更容易患各种需要医疗照护的慢性和急性疾病。此外，发作性睡病的增加、生活方式的改变以及导致发作性睡病的压力水平增加等因素预计将在预测期内推动市场扩张。此外，研究工作的增加、医疗保健支出的增加和医疗基础设施的增强预计将有助于未来几年发作性睡病药物市场的显着增长。中枢性嗜睡症的症状，例如昼夜节律延迟和睡眠增加，可以透过远距办公和改善睡眠条件来控制，从而进一步推动对发作性睡病治疗的需求。然而，高昂的治疗和诊断成本以及对发作性睡病现有治疗方法的认识有限等挑战可能会阻碍市场扩张。此外，不利的报销环境也限制了市场的成长。此外，製药公司标靶治疗研发的营业收入机会减少，在整个预测期内对发作性睡病治疗市场构成挑战。儘管存在这些挑战，但由于发作性睡患者病率的增加以及开发有效治疗方法的持续努力，预计市场将显着增长。

市场概况
北美洲
- 美国
- 加拿大
欧洲
- 德国
- 西班牙
- 法国
- 英国
- 欧洲其他地区
亚太地区
- 中国
- 印度
- 日本
- 韩国
- 亚太其他地区
拉丁美洲
- 巴西
- 拉丁美洲其他地区
中东和非洲 (MEA)
- 海湾合作委员会国家
- 南非
- MEA 的其余部分

竞争格局

前 5 名玩家比较
2023 年关键参与者的市场定位
主要市场参与者所采取的策略
最佳制胜策略
近期市集活动
主要公司市占率 (%), 2023

主要公司简介

Jazz Pharmaceuticals
Teva Pharmaceutical Industries
Novartis
Mylan NV
Shire Pharmaceuticals (acquired by Takeda Pharmaceutical Company Limited)
Ligand Pharmaceuticals
Bioprojet SCR
Arena Pharmaceuticals
Avadel Pharmaceuticals
Graymark Healthcare
Balance Pharmaceuticals
Theravance Biopharma
Biocodex
Flamel Technologies
Otsuka Pharmaceutical
Biogen
Aurobindo Pharma
Glenmark Pharmaceuticals
Lupin Pharmaceuticals

简介目录

Product Code: SQMIG35I2087

Global narcolepsy drugs market is expected to rise from USD 3.21 billion in 2022 and rise from USD 3.52 billion in 2023 to reach USD 7.32 billion by 2031, by rising at a CAGR of 9.60% during the forecast period (2024- 2031).

The narcolepsy drugs market is primarily driven by the aging population, who are more susceptible to various chronic and acute diseases requiring medical care. Additionally, factors such as the rise in narcoleptic diseases, changing lifestyles, and increased stress levels contributing to narcolepsy disorder are projected to fuel market expansion during the forecast period. Moreover, increased research efforts, rising healthcare expenditure, and enhanced medical infrastructure are expected to contribute to significant growth in the narcolepsy drugs market in the coming years. Symptoms of central hypersomnia, such as circadian delay and increased sleep, can be managed through teleworking and improved sleep conditions, further driving demand for narcolepsy treatments. However, challenges such as high treatment and diagnostic costs, as well as limited awareness about available treatments for narcolepsy, may hinder market expansion. Additionally, an unfavorable reimbursement environment poses a constraint to market growth. Furthermore, decreased operating revenue opportunities for targeted therapy research and development by pharmaceutical companies present challenges to the narcolepsy treatment market throughout the forecast period. Despite these challenges, the market is expected to witness significant growth driven by the increasing prevalence of narcolepsy and ongoing efforts to develop effective therapeutics.

Top-down and bottom-up approaches were used to estimate and validate the size of the global narcolepsy drugs market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Global Narcolepsy Drugs Market Segmental Analysis

Global narcolepsy drugs market is segmented based on the narcolepsy type, therapeutics, end user and region. By narcolepsy type, the market is segmented into cataplexy, and daytime extreme sleepiness. By therapeutics, the market is segmented into psychostimulants, tricyclic antidepressants, sodium oxybate, selective serotonin reuptake inhibitors, and central nervous system stimulants. By end user segment is segmented into hospitals, and diagnostic centres. By region, the market is segmented into North America, Europe, Asia-Pacific, Latin America, and MEA.

Drivers of the Global Narcolepsy Drugs Market

The narcolepsy market is experiencing significant growth from 2023 to 2030, driven by growing awareness of narcolepsy treatment options. The increasing adoption of modafinil, which has fewer adverse effects compared to other stimulants, is further fueling demand for narcolepsy treatment. As a result, the adoption of appropriate therapies plays a crucial role in preventing and managing narcolepsy, contributing to the market's expansion.

Restraints in the Global Narcolepsy Drugs Market

The lack of awareness surrounding narcolepsy symptoms often leads to misdiagnosis, with symptoms being mistaken for those of other mental and neurological conditions. Consequently, medications such as antiepileptics and psychiatric drugs are often prescribed, posing potential risks to the health of children and adolescents.

Market Trends of the Global Narcolepsy Drugs Market

The expanding prevalence of narcolepsy across diverse population groups globally serves as a significant growth catalyst for the narcolepsy market, with the escalating incidence of sleep disorders and hallucinations bolstering demand for narcolepsy drugs on a global scale. Moreover, the projected increase in obesity rates worldwide is poised to further fuel the market's expansion. Anticipated governmental initiatives aimed at raising awareness about narcolepsy are expected to drive demand for narcolepsy products in the foreseeable future. Hospital-based end-use is forecasted to be the primary contributor to market growth, fueled by the growing number of narcolepsy patients seeking treatment in these facilities.

Executive Summary

Market Overview
Wheel of Fortune

Research Methodology

Information Procurement
Secondary & Primary Data Sources
Market Size Estimation
Market Assumptions & Limitations

Parent Market Analysis

Market Overview
Market Size
Market Dynamics
- Drivers
- Opportunities
- Restraints
- Challenges

Key Market Insights

Technology Analysis
Pricing Analysis
Supply Chain Analysis
Value Chain Analysis
Ecosystem of the Market
IP Analysis
Trade Analysis
Startup Analysis
Raw Material Analysis
Innovation Matrix
Pipeline Product Analysis
Macroeconomic Indicators
Top Investment Analysis
Key Success Factor
Degree of Competition

Market Dynamics & Outlook

Market Dynamics
- Drivers
- Opportunities
- Restraints
- Challenges
Regulatory Landscape
Porters Analysis
- Competitive rivalry
- Threat of Substitute Products
- Bargaining Power of Buyers
- Threat of New Entrants
- Bargaining Power of Suppliers
Skyquest Special Insights on Future Disruptions
- Political Impact
- Economic Impact
- Social Impact
- Technical Impact
- Environmental Impact
- Legal Impact

Global Narcolepsy Drugs Market by Narcolepsy Type

Market Overview
Cataplexy
and Daytime Extreme Sleepiness.

Global Narcolepsy Drugs Market by Therapeutics

Market Overview
Psychostimulants
Tricyclic Antidepressants
Sodium Oxybate
Selective Serotonin Reuptake Inhibitors
Central Nervous System Stimulants.

Global Narcolepsy Drugs Market by End User

Market Overview
Hospitals
and Diagnostic Centres.a

Global Narcolepsy Drugs Market Size by Region

Market Overview
North America
- USA
- Canada
Europe
- Germany
- Spain
- France
- UK
- Rest of Europe
Asia Pacific
- China
- India
- Japan
- South Korea
- Rest of Asia-Pacific
Latin America
- Brazil
- Rest of Latin America
Middle East & Africa (MEA)
- GCC Countries
- South Africa
- Rest of MEA

Competitive Landscape

Top 5 Player Comparison
Market Positioning of Key Players, 2023
Strategies Adopted by Key Market Players
Top Winning Strategies
- By Development
- By Company
- By Year
Recent Activities in the Market
Key Companies Market Share (%), 2023

Key Company Profiles

Jazz Pharmaceuticals
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Teva Pharmaceutical Industries
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Novartis
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Mylan N.V.
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Shire Pharmaceuticals (acquired by Takeda Pharmaceutical Company Limited)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Ligand Pharmaceuticals
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Bioprojet SCR
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Arena Pharmaceuticals
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Avadel Pharmaceuticals
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Graymark Healthcare
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Balance Pharmaceuticals
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Theravance Biopharma
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Biocodex
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Flamel Technologies
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Otsuka Pharmaceutical
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Biogen
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Aurobindo Pharma
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Glenmark Pharmaceuticals
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Lupin Pharmaceuticals
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments